CN101724072B - 一种抗肿瘤的单克隆抗体的序列及应用 - Google Patents
一种抗肿瘤的单克隆抗体的序列及应用 Download PDFInfo
- Publication number
- CN101724072B CN101724072B CN 200810171904 CN200810171904A CN101724072B CN 101724072 B CN101724072 B CN 101724072B CN 200810171904 CN200810171904 CN 200810171904 CN 200810171904 A CN200810171904 A CN 200810171904A CN 101724072 B CN101724072 B CN 101724072B
- Authority
- CN
- China
- Prior art keywords
- antibody
- cancer
- tumour
- sequence
- variable region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 230000000259 anti-tumor effect Effects 0.000 title description 2
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 80
- 206010009944 Colon cancer Diseases 0.000 claims abstract description 33
- 201000007270 liver cancer Diseases 0.000 claims abstract description 18
- 208000014018 liver neoplasm Diseases 0.000 claims abstract description 18
- 206010006187 Breast cancer Diseases 0.000 claims abstract description 11
- 208000026310 Breast neoplasm Diseases 0.000 claims abstract description 11
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims abstract description 11
- 206010033128 Ovarian cancer Diseases 0.000 claims abstract description 11
- 206010061535 Ovarian neoplasm Diseases 0.000 claims abstract description 11
- 201000005202 lung cancer Diseases 0.000 claims abstract description 11
- 208000020816 lung neoplasm Diseases 0.000 claims abstract description 11
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 20
- 201000010989 colorectal carcinoma Diseases 0.000 claims description 13
- 238000010353 genetic engineering Methods 0.000 claims description 9
- 230000027455 binding Effects 0.000 claims description 7
- 239000012634 fragment Substances 0.000 claims description 6
- 125000000539 amino acid group Chemical group 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 238000013016 damping Methods 0.000 claims description 3
- 239000012530 fluid Substances 0.000 claims description 3
- 230000004927 fusion Effects 0.000 claims description 3
- 239000000654 additive Substances 0.000 claims description 2
- 230000000996 additive effect Effects 0.000 claims description 2
- 239000003981 vehicle Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 abstract description 10
- 239000003814 drug Substances 0.000 abstract description 8
- 239000000203 mixture Substances 0.000 abstract description 5
- 206010061902 Pancreatic neoplasm Diseases 0.000 abstract 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 abstract 1
- 201000002528 pancreatic cancer Diseases 0.000 abstract 1
- 208000008443 pancreatic carcinoma Diseases 0.000 abstract 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 21
- 210000001519 tissue Anatomy 0.000 description 21
- 201000011510 cancer Diseases 0.000 description 14
- 238000012216 screening Methods 0.000 description 10
- 241000282414 Homo sapiens Species 0.000 description 9
- 239000000427 antigen Substances 0.000 description 8
- 102000036639 antigens Human genes 0.000 description 8
- 108091007433 antigens Proteins 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- 101710181478 Envelope glycoprotein GP350 Proteins 0.000 description 6
- 229940125644 antibody drug Drugs 0.000 description 6
- 238000003745 diagnosis Methods 0.000 description 6
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 5
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 210000000170 cell membrane Anatomy 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000000502 dialysis Methods 0.000 description 3
- 238000013399 early diagnosis Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 238000012151 immunohistochemical method Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 238000004091 panning Methods 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 201000000498 stomach carcinoma Diseases 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- WVRUNFYJIHNFKD-WDSKDSINSA-N Arg-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](N)CCCN=C(N)N WVRUNFYJIHNFKD-WDSKDSINSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 241001524679 Escherichia virus M13 Species 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 240000002853 Nelumbo nucifera Species 0.000 description 2
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 2
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 239000000287 crude extract Substances 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 238000011580 nude mouse model Methods 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 1
- YZQCXOFQZKCETR-UWVGGRQHSA-N Asp-Phe Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 YZQCXOFQZKCETR-UWVGGRQHSA-N 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- MADFVRSKEIEZHZ-DCAQKATOSA-N Gln-Gln-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)N)N MADFVRSKEIEZHZ-DCAQKATOSA-N 0.000 description 1
- JZOYFBPIEHCDFV-YUMQZZPRSA-N Gln-His Chemical compound NC(=O)CC[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CN=CN1 JZOYFBPIEHCDFV-YUMQZZPRSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- TWVKGYNQQAUNRN-ACZMJKKPSA-N Ile-Ser Chemical compound CC[C@H](C)[C@H]([NH3+])C(=O)N[C@@H](CO)C([O-])=O TWVKGYNQQAUNRN-ACZMJKKPSA-N 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- LZDNBBYBDGBADK-UHFFFAOYSA-N L-valyl-L-tryptophan Natural products C1=CC=C2C(CC(NC(=O)C(N)C(C)C)C(O)=O)=CNC2=C1 LZDNBBYBDGBADK-UHFFFAOYSA-N 0.000 description 1
- 108010066427 N-valyltryptophan Proteins 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- LTFSLKWFMWZEBD-IMJSIDKUSA-N Ser-Asn Chemical compound OC[C@H](N)C(=O)N[C@H](C(O)=O)CC(N)=O LTFSLKWFMWZEBD-IMJSIDKUSA-N 0.000 description 1
- LAFKUZYWNCHOHT-WHFBIAKZSA-N Ser-Glu Chemical compound OC[C@H](N)C(=O)N[C@H](C(O)=O)CCC(O)=O LAFKUZYWNCHOHT-WHFBIAKZSA-N 0.000 description 1
- YZMPDHTZJJCGEI-BQBZGAKWSA-N Ser-His Chemical compound OC[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CNC=N1 YZMPDHTZJJCGEI-BQBZGAKWSA-N 0.000 description 1
- UQTNIFUCMBFWEJ-IWGUZYHVSA-N Thr-Asn Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@H](C(O)=O)CC(N)=O UQTNIFUCMBFWEJ-IWGUZYHVSA-N 0.000 description 1
- BQBCIBCLXBKYHW-CSMHCCOUSA-N Thr-Leu Chemical compound CC(C)C[C@@H](C([O-])=O)NC(=O)[C@@H]([NH3+])[C@@H](C)O BQBCIBCLXBKYHW-CSMHCCOUSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- LZDNBBYBDGBADK-KBPBESRZSA-N Val-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](N)C(C)C)C(O)=O)=CNC2=C1 LZDNBBYBDGBADK-KBPBESRZSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical class N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 108010069205 aspartyl-phenylalanine Proteins 0.000 description 1
- 238000001815 biotherapy Methods 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 201000005619 esophageal carcinoma Diseases 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 238000010827 pathological analysis Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000000505 pernicious effect Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000452 restraining effect Effects 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 102220023257 rs387907546 Human genes 0.000 description 1
- 102220023256 rs387907547 Human genes 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 108010048818 seryl-histidine Proteins 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
Images
Landscapes
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200810171904 CN101724072B (zh) | 2008-10-27 | 2008-10-27 | 一种抗肿瘤的单克隆抗体的序列及应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200810171904 CN101724072B (zh) | 2008-10-27 | 2008-10-27 | 一种抗肿瘤的单克隆抗体的序列及应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101724072A CN101724072A (zh) | 2010-06-09 |
CN101724072B true CN101724072B (zh) | 2013-10-09 |
Family
ID=42445683
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 200810171904 Expired - Fee Related CN101724072B (zh) | 2008-10-27 | 2008-10-27 | 一种抗肿瘤的单克隆抗体的序列及应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101724072B (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106432490B (zh) * | 2016-09-14 | 2020-01-07 | 北京大学 | 一种abcg2单克隆抗体及其用途 |
CN113203858B (zh) * | 2021-05-06 | 2021-12-07 | 潍坊三维生物工程集团有限公司 | 一种肿瘤检测试剂盒 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1051389A (zh) * | 1989-06-30 | 1991-05-15 | 翁科根两合公司 | 作用于人体癌的新型抗体 |
US5185432A (en) * | 1986-02-26 | 1993-02-09 | Oncogen | Monoclonal antibodies and antigen for human non-small cell lung carcinoma and other certain human carcinomas |
CN1584028A (zh) * | 2004-06-10 | 2005-02-23 | 上海富纯中南生物技术有限公司 | 用于筛选肿瘤坏死靶向抗体的克隆及其制备方法和用途 |
CN101084013A (zh) * | 2004-09-15 | 2007-12-05 | 阿里乌斯研究公司 | 癌症调节抗体 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7468254B2 (en) * | 2003-01-21 | 2008-12-23 | Arius Research Inc. | Cytotoxicity mediation of cells evidencing surface expression of MCSP |
-
2008
- 2008-10-27 CN CN 200810171904 patent/CN101724072B/zh not_active Expired - Fee Related
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5185432A (en) * | 1986-02-26 | 1993-02-09 | Oncogen | Monoclonal antibodies and antigen for human non-small cell lung carcinoma and other certain human carcinomas |
CN1051389A (zh) * | 1989-06-30 | 1991-05-15 | 翁科根两合公司 | 作用于人体癌的新型抗体 |
CN1584028A (zh) * | 2004-06-10 | 2005-02-23 | 上海富纯中南生物技术有限公司 | 用于筛选肿瘤坏死靶向抗体的克隆及其制备方法和用途 |
CN101084013A (zh) * | 2004-09-15 | 2007-12-05 | 阿里乌斯研究公司 | 癌症调节抗体 |
Non-Patent Citations (9)
Title |
---|
EGFR 单克隆抗体抗结肠癌作用的实验研究;曲娴等;《中国病理生理杂志》;20020915;第18卷(第9期);第1130-1132页 * |
Inhibited growth of colon cancer carcinomatosis by antibodies to vascular endothelial and epidermal growth factor receptors;RM Shaheen等;《British Journal of Cancer》;20010831;第85卷(第4期);第584-589页 * |
Mikael Dohlsten等.Immunotherapy of human colon cancer by antibody-targeted superantigens.《Cancer Immunology,Immunotherapy》》.1995,第41卷(第3期),第162-168页. * |
RM Shaheen等.Inhibited growth of colon cancer carcinomatosis by antibodies to vascular endothelial and epidermal growth factor receptors.《British Journal of Cancer》.2001,第85卷(第4期),第584-589页. |
全人源化抗结肠癌单链抗体基因的克隆和表达;朱建高等;《生物工程学报》;20010930;第17卷(第5期);第526-530页 * |
曲娴等.EGFR 单克隆抗体抗结肠癌作用的实验研究.《中国病理生理杂志》.2002,第18卷(第9期),第1130-1132页. |
朱建高等.全人源化抗结肠癌单链抗体基因的克隆和表达.《生物工程学报》.2001,第17卷(第5期),第526-530页. |
王荣福等.结肠癌单克隆抗体的制备和鉴定.《中国免疫学杂志》.1988,第4卷(第4期),第230-232页、250页、封3. |
结肠癌单克隆抗体的制备和鉴定;王荣福等;《中国免疫学杂志》;19880430;第4卷(第4期);第230-232页、250页、封3 * |
Also Published As
Publication number | Publication date |
---|---|
CN101724072A (zh) | 2010-06-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107880130B (zh) | 一种具有高亲和力的抗癌胚抗原纳米抗体及应用 | |
CN111499750B (zh) | 一种抗癌胚抗原的高中和活性纳米抗体及其应用 | |
JP2018531219A (ja) | Pd−l1抗体 | |
JP2020182492A (ja) | 抗cd137抗体 | |
CN110642951B (zh) | 一种抗ca125糖类抗原的高中和活性纳米抗体及其应用 | |
WO2020151122A1 (zh) | 抗人pcsk9单克隆抗体及其用途 | |
CN113234166B (zh) | 一种抗afp的纳米抗体1c5及其应用 | |
JP2023523600A (ja) | ヒトプログラム細胞死リガンド1(pd-l1)を標的とする単一可変ドメイン抗体およびその誘導体 | |
CN103153340A (zh) | 对肿瘤疾病的治疗 | |
KR20170039074A (ko) | Tmcc3의 억제에 의한 암 저해 방법 | |
CN114380910A (zh) | 靶向人b7-h3分子的人源化单克隆抗体及其应用 | |
CN101724072B (zh) | 一种抗肿瘤的单克隆抗体的序列及应用 | |
CN112513086A (zh) | Cd226激动剂抗体 | |
US20220289825A1 (en) | FUSION PROTEIN TARGETING PD-L1 AND TGF-ß AND USE THEREOF | |
CN113173994A (zh) | 一种抗afp的纳米抗体1a7及其应用 | |
EP3288979B1 (en) | Igf-1r antibody and its use for the diagnosis of cancer | |
WO2023024444A1 (zh) | 抗msln单克隆内化抗体及其制备方法和应用 | |
CN113880948B (zh) | 抗ca724抗体或其抗原结合片段及其制备方法和应用 | |
CN113214399B (zh) | 一种抗afp的纳米抗体2f5及其应用 | |
CN111004328A (zh) | 一种用于双抗体夹心法检测癌胚抗原的纳米抗体组合 | |
EP3288978B1 (en) | Igf-1r antibody and its use for the diagnosis of cancer | |
CN115232212B (zh) | 一种trop-2特异性纳米抗体及其应用 | |
CN114380913B (zh) | 一种全人源抗pd-l1抗体及其应用 | |
CN117343194B (zh) | 靶向pd-l1/hsa/ccl5三特异性纳米抗体及其衍生物和应用 | |
CN111787946B (zh) | 抗-类egf结构域多重6(egfl6)抗体及其于癌症诊断及治疗中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
DD01 | Delivery of document by public notice |
Addressee: Gu Weiyue Document name: the First Notification of an Office Action |
|
C53 | Correction of patent for invention or patent application | ||
CB02 | Change of applicant information |
Address after: 100029, Room 201, North building, miracle Fortune Plaza, Chaoyang District, Beijing Applicant after: Gu Weiyue Address before: 101400, room 1, gate 601, building 31, Qingchun Road, Huairou District, Beijing Applicant before: Gu Weiyue |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20151228 Address after: 100176 Beijing City Economic and Technological Development Zone Branch Street 88 Hospital No. 6 Building 3 unit 507 room Patentee after: Beijing card Medical Technology Co., Ltd. Address before: 100029, Room 201, North building, miracle Fortune Plaza, Chaoyang District, Beijing Patentee before: Gu Weiyue |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20131009 Termination date: 20181027 |